- WKN: 575381
- ISIN: DE0005753818
- Land: Deutschland
Nachricht vom 02.05.2012 | 10:04
Press Release 4SC AG: Dr Jörg Neermann announces resignation from Supervisory Board of 4SC AG
4SC AG / Key word(s): Change of Personnel/Miscellaneous
4SC AG: Dr Jörg Neermann announces resignation from Supervisory Board
Planegg-Martinsried, Germany, 2 May 2012 - 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that Dr Jörg Neermann has informed the company that he will resign from his position as chairman and member of the Supervisory Board of 4SC AG effective 31 May 2012. Dr Neermann is resigning of his own accord and for personal reasons. Dr Neermann has been a member of the Supervisory Board of 4SC AG since 3 August 2000 and previously had been a member of the Advisory Board of the predecessor company, 4SC GmbH.
4SC thanks Dr Neermann for his many years of commendable service and his dedication to the work of the Supervisory Board. Dr Thomas Werner, deputy chairman of the Supervisory Board of 4SC AG, will be assuming the position of chairman of the Supervisory Board on an interim basis from 1 June 2012. Following the departure of Dr Neermann, the Supervisory Board will initiate proceedings for the election of a new Supervisory Board chairman and deputy chairman as soon as possible.
Dr Thomas Werner, deputy chairman of the 4SC Supervisory Board, said: 'Dr Neermann has made an outstanding contribution to the company's prestige and to the establishment of 4SC as one of Germany's most innovative biotechnology companies. We regret that Dr Neermann will be leaving us and thank him for his dedication over the years and his successful work as chairman of the 4SC Supervisory Board.'
Dr Ulrich Dauer, Chief Executive Officer of 4SC AG, commented: 'Dr Neermann has contributed invaluable support to and had decisive impact on the successful development of 4SC for over 13 years. Not only as an investor in all of the company's rounds of venture capital financing, from the initial financing in 1999 to the public listing in 2005, but also as a member - and, from 2003, as chairman - of the 4SC Supervisory Board. On behalf of the entire 4SC Management Board and the entire company, I wish to thank Dr Neermann for his magnificent contribution to 4SC's success and for his dedicated and constructive collaboration as a friend of our company. I wish him all the best for the future.'
The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 96 employees at the end of 2011. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com or contact:
The Trout Group (USA)
End of Corporate News
02.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
|Am Klopferspitz 19a|
|Phone:||+49 (0)89 7007 63-0|
|Fax:||+49 (0)89 7007 63-29|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
|End of News||DGAP News-Service|
Press Release: 4SC significantly improves oper ...
Announcement: 4SC to host conference call on 1 ...
Press Release: 4SC to present at two upcoming ...
4 SC AG: Bekanntmachung der Einberufung zur Ha ...
Press Release: 4SC announces financial results ...
Anleihe im Fokus
Die DF-Anleihe 7,875%
Mit der DF Forfait AG vom wachsenden Welthandel profitieren
- Zeichnungsfrist: 21.05. bis 24.05.2013
- Laufzeit: 7 Jahre
- Kupon: 7,875% p.a.
- Volumen: bis zu 30 Mio. Euro
- ISIN: DE000A1R1CC4
Anleihe im Fokus
7,75% p.a. - Rendite aus Familienhand
– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs
HELMA Eigenheimbau AG: Kaufen
Die HELMA Eigenheimbau AG präsentierte für das Geschäftsjahr 2012 Rekordwerte. Auf Basis unseres DCF-Modells haben wir einen fairen Wert je Aktie von 22,75 € ermittelt. Ausgehend vom erwarteten 2013er-EPS von 1,64 € entspricht dies einem KGV von 8,4. Das Kurspotenzial beläuft sich auf nahezu 65%.
Der AKTIONÄR News
20. Mai 10:00 Linde: Die heimliche DAX-Perle
Analysts' conference call on 1Q 2013
15. Mai 2013
Original-Research: Plan Optik AG (von GBC AG): Kaufen Plan Optik AG
17. Mai 2013